Objective-We examined the function of ABCA1 (ATP-binding cassette transporter A1) in ApoA-I (apolipoprotein A-I) mobilization of cholesterol microdomains deposited into the extracellular matrix by cholesterol-enriched macrophages. We have also determined whether an ApoA-I mimetic peptide without and with complexing to sphingomyelin can mobilize macrophage-deposited cholesterol microdomains.
A therosclerotic plaques show accumulation of both intracellular and extracellular lipid. Our earlier studies show that much unesterified cholesterol accumulates within the extracellular matrix of human atherosclerotic plaques. [1] [2] [3] Thus, strategies to decrease lipid accumulation by stimulating reverse cholesterol transport from plaque cholesterol-containing cells should also address how to mobilize extracellular cholesterol deposits.
Recently, we have shown that macrophages contribute to extracellular deposits of unesterified cholesterol by depositing excess cholesterol into the extracellular matrix. [4] [5] [6] Depending on the macrophage type and culture conditions, macrophages enriched with cholesterol show development of cholesterol microdomains that are associated with the plasma membrane or that macrophages deposit into the extracellular matrix. [4] [5] [6] We have visualized these cholesterol microdomains with a unique monoclonal antibody that immunolabels an ordered array of cholesterol molecules. 7 Both ABCA1 (ATP-binding cassette transporter A1) and ABCG1 (ATP-binding cassette transporter G1) mediate extracellular deposition of the cholesterol microdomains by mouse bone marrow-derived macrophages, whereas ABCA1 mediates their deposition by human macrophage colony-stimulating factor-differentiated monocyte-derived macrophages. 4, 5 This previously unrecognized pool of extracellular cholesterol microdomains can be mobilized by high-density lipoprotein, cyclodextrin, and ApoA-I (apolipoprotein A-I). 4, 6 However, in contrast to high-density lipoprotein, ApoA-I mobilization of the cholesterol microdomains depends on the presence of macrophages. 6 The fact that the cholesterol microdomains deposited by macrophages can be mobilized by high-density lipoprotein and ApoA-I shows that the extracellular cholesterol microdomains can potentially function in the reverse cholesterol transport pathway.
There has been much interest in the development of ApoA-I mimetic peptides that could be administered to patients as treatment for atherosclerosis. [8] [9] [10] ApoA-I mimetics would hopefully promote reverse cholesterol transport and thus decrease cholesterol build-up in atherosclerotic plaques. The advantage of administering ApoA-I mimetic peptides compared with administration of ApoA-I itself would be a lesser cost to produce the mimetic peptides and the possibility that these peptide mimetics could be administered orally. To date, clinical trials of some early ApoA-I mimetics have shown limited efficacy and unexpected toxicities. 9, 10 However, refinement of the peptides may allow for enhancement of their cholesterol mobilization properties and diminished toxicity.
One such refined ApoA-I mimetic peptide is 5A, which has been shown to stimulate cholesterol efflux from a mouse macrophage cell line and to decrease atherosclerosis in a mouse model of atherosclerosis. 11 Peptide 5A is a 37-amino acid-long bihelical amphipathic peptide that contains an 18A α-helix sequence in the first helix as described previously, 12 joined by a proline with a modified 18A sequence containing 5 Ala substitutions in the second helix. 13 Similar to ApoA-I and other ApoA-I mimetic peptides, peptide 5A can be complexed with phospholipids such as sphingomyelin to increase their potential to stimulate cellular cholesterol efflux independent of ABCA1. 11, 14 To further investigate the potential efficacy of peptide 5A for human therapy of atherosclerosis, we have examined whether this ApoA-I mimetic peptide can mobilize the extracellular cholesterol microdomains deposited by cholesterolenriched human monocyte-derived macrophages. Also, we have tested whether ApoA-I and peptide 5A require ABCA1 function in order for these agents to mobilize the extracellular cholesterol microdomains deposited by macrophages. Last, we compared the efficacy of ApoA-I and peptide 5A with peptide 5A complexed with sphingomyelin in mobilization of extracellular cholesterol microdomains. Our findings indicate that while ApoA-I and peptide 5A depend on ABCA1 function for their efficacy in mobilizing extracellular cholesterol microdomains, peptide 5A complexed with sphingomyelin can mobilize extracellular cholesterol microdomains independent of ABCA1 function.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

ApoA-I and ApoA-I Mimetic Peptide 5A Mobilize Extracellular Cholesterol Microdomains Deposited by Macrophages
Human macrophage colony-stimulating factor-differentiated monocyte-derived macrophages were cholesterol enriched by 1-day incubation with acetylated low-density lipoprotein (50 µg/mL). During this incubation, macrophages deposited cholesterol (detected with monoclonal antibody [Mab]58B1) into the extracellular matrix surrounding the macrophages as we reported previously. [4] [5] [6] After rinsing of the cultures and subsequent 1-day incubation with peptide 5A, peptide 5A-sphingomyelin, or ApoA-I, Mab58B1 immunostaining was eliminated consistent with mobilization of the extracellular cholesterol microdomains (Figure 1 ). In contrast, cholesterol was not mobilized when macrophages were incubated with control peptide EE or with no addition. The effect of peptide 5A was concentration dependent with a maximal effect observed at a concentration of 40 µg/mL ( Figure I in the online-only Data Supplement). On the contrary, peptide EE sometimes ( Figure 1 ), but not always ( Figure I in the online-only Data Supplement) increased extracellular cholesterol microdomain immunostaining for reasons that are not clear to us.
We also assessed the cholesterol content of cholesterolenriched macrophages after incubation with ApoA-I and the
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ATP-binding cassette transporter A1 ABCG1 ATP-binding cassette transporter G1 ApoA-I mimetic peptide. Peptide 5A, peptide 5A-sphingomyelin, and ApoA-I all caused large and similar decreases in cholesterol content of the cholesterol-enriched human macrophages (≈170-190 nmoles cholesterol/mg cell protein equivalent to ≈70% of the accumulated cholesterol; Figure 2 ). Sphingomyelin added alone without having been complexed with peptide 5A did not decrease macrophage cholesterol content. Peptide EE showed some decrease in macrophage cholesterol content, but the amount (39±8 nmoles cholesterol/mg cell protein) was much less than that of peptide 5A.
Unless Complexed With Sphingomyelin, ApoA-I Mimetic Peptide 5A Does Not Mobilize Extracellular Cholesterol Microdomains in Absence of Macrophages
Previously, we reported that ApoA-I could not mobilize extracellular cholesterol microdomains when macrophages were removed from the culture. 6 Therefore, we examined whether peptide 5A could mobilize extracellular cholesterol microdomains in the absence of macrophages. First, human macrophages were cholesterol enriched by incubation with acetylated low-density lipoprotein as described above except that incubation was for 2 days with the liver X receptor agonist, TO901317 (TO9), added to induce maximally ABCA1 and ABCG1 that we previously showed to mediate macrophage deposition of extracellular cholesterol microdomains. 4, 5 Then, macrophages were removed from one set of cultures leaving only the extracellular macrophage-deposited cholesterol. Macrophages were not removed in a duplicate set of cultures. Both sets of cultures without and with macrophages were then incubated 1 day without and with the various peptides followed by Mab58B1 immunostaining of cholesterol microdomains.
Without the presence of macrophages during the incubation with peptides or ApoA-I, only peptide 5A-sphingomyelin mobilized cholesterol from the extracellular matrix ( Figure 3 ). However, as compared with its effect with macrophages present, some patches of extracellular Mab58B1 immunostaining remained. This experiment with intensified deposition of cholesterol microdomains showed that in the presence of macrophages, peptide 5A-sphingomyelin completely eliminated Mab58B1 immunostaining, whereas peptide 5A and ApoA-I only partially decreased Mab58B1 immunostaining. This is contrast to the experiment above (Figure 1) , where peptide 5A, peptide 5A-sphingomyelin, and ApoA-I completely eliminated extracellular Mab58B1 immunostaining in the presence of macrophages.
The extracellular cholesterol microdomains that underlie cholesterol-enriched macrophages were not simply cell debris left behind on the culture surface. This was the case because CD14, a macrophage plasma membrane marker, 15 while present on the macrophage surface, was not present in the extracellular matrix ( Figure II in the online-only Data Supplement).
Unless Complexed With Sphingomyelin, ApoA-I Mimetic Peptide 5A Fails to Mobilize Extracellular Cholesterol Microdomains Deposited by ABCA −/− Mouse Macrophages
Peptide 5A mobilization of macrophage-deposited cholesterol microdomains depended on the continued presence of macrophages, whereas peptide 5A-sphingomyelin complex mobilization of extracellular cholesterol microdomains did not depend on macrophages. This suggests that macrophages were necessary for peptide 5A efficacy possibly by providing ABCA1-mediated complexing of macrophage phospholipid with peptide 5A as occurs with ApoA-I. 16 We examined this possibility.
First, we determined the degree of mobilization of macrophage-deposited cholesterol microdomains during a 2-day incubation with peptide 5A. In contrast to the 1-day incubation with peptide 5A as shown above in Figure 3 , where Mab58B1 immunostaining was only partially decreased, a 2-day incubation showed complete elimination of Mab58B1 immunostaining (Figure 4 ). Peptide 5A-sphingomyelin and ApoA-I (but not peptide EE) showed a similar elimination of Mab58B1 immunostaining. However, this was not the case when ABCA1 −/− mouse macrophages were tested. In this case, only peptide 5A-sphingomyelin could mobilize extracellular cholesterol microdomains but peptide 5A and ApoA-I could not ( Figure 5 ). Thus, ABCA1 was necessary for peptide 5A and ApoA-I mobilization of extracellular cholesterol microdomains.
We next assessed the importance of ABCA1 for macrophage cholesterol mass efflux mediated by peptides 5A and 5A-sphingomyelin. Similar to human macrophages, peptides 5A and 5A-sphingomyelin caused a substantial decrease in Figure 2 . ApoA-I (apolipoprotein A-I) mimetic peptide 5A substantially decreases macrophage cholesterol content. One-wkold human macrophage colony-stimulating factor-differentiated monocyte-derived macrophage cultures were incubated 1 d with 50 µg/mL acetylated low-density lipoprotein (AcLDL) to enrich macrophages with cholesterol. After rinsing, macrophage cultures were incubated 1 d with the indicated additions (20 μg/ mL ApoA-I, 100 μg/mL peptide, and 125 µg/mL sphingomyelin alone or complexed with 100 μg/mL peptide 5A [5A-SPH]) without AcLDL. Then, the macrophage total cholesterol content was determined, and the decrease in macrophage total cholesterol content induced by the added agent was calculated. Macrophage total cholesterol contents before and after incubation with AcLDL were 98±2 nmoles cholesterol/mg cell protein (5±3% cholesteryl ester) and 305±7 nmoles cholesterol/mg cell protein (30±1% cholesteryl ester), respectively. The percentage decrease in net total cholesterol accumulation is listed above the bar. ApoA-I, 5A, and 5A-SPH were all significantly different than EE and SPH. EE indicates peptide EE; and f/b, followed by. December 2016 cholesterol content (218±15 and 309±25 nmoles cholesterol/mg cell protein, respectively) in cholesterol-enriched ABCA1 +/+ (wild type) mouse macrophages ( Figure 6 ). Also, similar to human macrophages, the control peptide EE decreased cholesterol content substantially less (61±18 nmoles cholesterol/mg cell protein) than the ApoA-I mimetic peptide 5A. However, only peptide 5A-sphingomyelin significantly decreased the cholesterol content of cholesterol-enriched ABCA1 −/− mouse macrophages ( Figure 6 ). This showed that peptide 5A required macrophage ABCA1 to stimulate macrophage cholesterol efflux.
Isolated Cholesterol Microdomains Contain Cholesterol that Is Unestified
The anticholesterol microdomain Mab58B1 shows the presence of cholesterol in the extracellular deposits, and we previously showed that the deposits do not stain with Oil Red O indicating the lack of cholesteryl ester. 4 However, to confirm that the cholesterol microdomains contain cholesterol in a predominantly unestified form, we analyzed the cholesterol composition of the extracellular cholesterol microdomains. We isolated the cholesterol microdomains by first removing macrophages from culture wells using EDTA and then releasing the microdomains from the extracellular matrix by trypsin treatment. This was followed by density gradient centrifugation of the released cholesterol microdomains ( Figure  III in the online-only Data Supplement). The density gradient showed 3 regions of cholesterol at densities ≤1.005, 1.030 to 1.044, and ≥1.091 g/mL showing 51%, 91%, and 95% of cholesterol that was unesterified, respectively. The cholesteryl ester in the density ≤1.005 region is likely extracellular matrix-bound acetylated low-density lipoprotein that floats after loss of protein after exposure to protease. 17 Mab58B1 immunostaining of the isolated cholesterol particles from each cholesterol-rich density gradient region showed that the density 1.030 to 1.044 g/mL cholesterol region was most enriched with cholesterol microdomains that stained with the anticholesterol microdomain Mab58B1 ( Figure III in the online-only Data Supplement). 
Discussion
ApoA-I and ApoA-I mimetic peptide 5A mobilization of extracellular cholesterol microdomains depended on ABCA1. The cholesterol microdomains deposited by macrophages could not be directly solubilized by peptide 5A or ApoA-I. This is presumably because ABCA1 mediates complexing of cell-derived phospholipid with ApoA-I and ApoA-I mimetic peptides, 16 and it is the phospholipid that solubilizes cholesterol. Under certain conditions, ApoA-I and ApoA-I mimetic peptides can directly solubilize phospholipid and form complexes without ABCA1. 18, 19 However, this depends on the phospholipid type and the amount of cholesterol associated with the phospholipid. 20 The fact that the cholesterol microdomains could not be directly solubilized by ApoA-I or the ApoA-I mimetic peptide suggests that the cholesterol microdomains are not associated with a cholesterol-solubilizing lipid that is susceptible to amphipathic apolipoprotein-induced micellarization.
Interestingly, an ApoA-I-binding site has been described in the extracellular matrix underlying macrophages. 21 Thus, this binding site localizes ApoA-I to the same location where the extracellular cholesterol microdomains deposit. Because the ApoA-I-binding site mediates ABCA1-dependent cholesterol efflux, this binding site could be functioning in mobilization of the macrophage-deposited cholesterol microdomains.
The cholesterol pool that is mobilized by ApoA-I interaction with ABCA1 has been postulated to be present within the plasma membrane, [22] [23] [24] [25] [26] [27] intracellularly within late endosomes/ lysosomes, [28] [29] [30] [31] [32] [33] and within the extracellular matrix as we have shown here. It is possible that efflux from all these cholesterol pools could be occurring simultaneously or individually depending on the cell type under study. Also, intracellular ApoA-I mimetic peptide 5A mobilize extracellular cholesterol microdomains deposited by ABCA +/+ mouse macrophages. One-wk-old ABCA1 +/+ mouse macrophage colony-stimulating factor-differentiated bone marrow-derived macrophage cultures were incubated 2 d with 50 µg/mL acetylated low-density lipoprotein (AcLDL)+5 μm TO901317 (TO9) to enrich macrophages with cholesterol. After rinsing, macrophage cultures were incubated 2 days with the indicated additions (20 µg ApoA-I, 100 μg/mL peptide, and 125 µg/mL sphingomyelin complexed with 100 μg/mL peptide 5A [5A-SPH]) without AcLDL. Left, Cholesterol microdomains were visualized by fluorescence microscopy using anticholesterol microdomain Mab58B1 (green), and nuclei were imaged with DAPI fluorescence staining (blue). Right, Macrophages were visualized using phase-contrast microscopy. Left and right, Corresponding microscopic fields. f/b indicates followed by. Bar=50 µm and applies to all. Figure 5 . Unless complexed with sphingomyelin, ApoA-I (apolipoprotein A-I) mimetic peptide 5A fails to mobilize extracellular cholesterol microdomains deposited by ABCA −/− mouse macrophages. One-wk-old ABCA1 −/− mouse macrophage colony-stimulating factor-differentiated bone marrow-derived macrophage cultures were incubated 2 d with 50 µg/mL acetylated low-density lipoprotein (AcLDL)+5 μm TO901317 (TO9) to enrich macrophages with cholesterol. After rinsing, macrophage cultures were incubated 2 d with the indicated additions (20 µg ApoA-I, 100 µg/ mL peptide, and 125 µg/mL sphingomyelin complexed with 100 µg/mL peptide 5A [5A-SPH]) without AcLDL. Left, Cholesterol microdomains were visualized by fluorescence microscopy using anticholesterol microdomain Mab58B1 (green), and nuclei were imaged with DAPI fluorescence staining (blue). Right, Macrophages were visualized using phase-contrast microscopy. Left and right, Corresponding microscopic fields. f/b indicates followed by. Bar=50 µm and applies to all. cholesterol pools may be a source of cholesterol that is available for efflux within the plasma membrane or extracellular matrix. In this regard, ABCA1 redistributes intracellular cholesterol to cholesterol oxidase-sensitive pools of cholesterol that could be located within either the plasma membrane or the extracellular cholesterol microdomains we have described. 4, 23, 34 Previous investigations of ApoA-I-mediated cellular cholesterol efflux have suggested that cholesterol is concurrently effluxed with the phospholipid that complexes with ApoA-I (one-step process). 23, 30, 35, 36 Simultaneous complexing of phospholipid and cholesterol with ApoA-I has been suggested to result from microsolubilization of plasma membrane microdomains. 37 Both nonraft and raft microdomains, the latter characterized by sphingomyelin and cholesterol enrichment, may contribute to such ApoA-I-lipid complexes. [38] [39] [40] Alternatively, ApoA-I could complex with phospholipid before the complex acquiring cholesterol from the cell (2-step process). 35, [41] [42] [43] [44] The findings that ABCA1-mediated phospholipid efflux can occur without cholesterol efflux and that cholesterol efflux can be regulated independent of phospholipid efflux in some cell systems could be interpreted to support a 2-step process. 33, 35, [41] [42] [43] [44] [45] [46] [47] Our findings show that in the case of extracellular cholesterol microdomains, a 2-step process mediates cholesterol efflux from the extracellular matrix. First, macrophages excrete cholesterol microdomains into the extracellular matrix, and subsequently interaction of ApoA-I with macrophage ABCA1 mobilizes the cholesterol microdomains.
We have shown previously that ABCA1 and ABCG1 mediate macrophage deposition of cholesterol microdomains into the extracellular matrix. 4, 5 Thus, ABCA1 shows 2 separate functions: one that mediates deposition of the extracellular cholesterol microdomains and another that mediates ApoA-I's mobilization of the extracellular microdomains.
Dependence on ABCA1 to mediate complexing of phospholipid with ApoA-I and ApoA-I mimetic peptides could be a rate limiting process in reverse cholesterol transport from atherosclerotic plaques because ABCA1 expression in human atherosclerotic plaques is diminished. Studies have shown that ABCA1 expression in human atherosclerotic plaques is limited because of the differentiation state of intimal smooth muscle cells 48 and in the case of macrophages possibly because of the fact that ABCA1 is downregulated by various cytokines likely present within atherosclerotic plaques. 49 Moreover, much of the cholesterol within human atherosclerotic plaques accumulates in relatively acellular plaque regions where there would not be any cellular expression of ABCA1. 50 In these acellular regions, there is no possibility to locally complex either ApoA-I or ApoA-I mimetic peptides with cell-derived phospholipid.
Given that much of the cholesterol in human atherosclerotic plaques accumulates within the extracellular space, [1] [2] [3] 6 mobilizing extracellular cholesterol microdomains may be as important as mobilizing cholesterol stored within atherosclerotic plaque cells. Because of dependence on ABCA1 as discussed above, peptide 5A and ApoA-I could not mobilize extracellular cholesterol microdomains deposited by macrophages when macrophages were removed from the cultures or when macrophages lacked ABCA1. In contrast, peptide 5A complexed with sphingomyelin could mobilize extracellular cholesterol microdomains under these conditions showing the potential usefulness of preformed ApoA-I mimetic-phospholipid complexes in mobilizing extracellular cholesterol microdomains even in the absence of ABCA1. Figure 6 . ApoA-I (apolipoprotein A-I) mimetic peptide 5A substantially decreases ABCA +/+ but not ABCA −/− mouse macrophage cholesterol content. One-wk-old mouse macrophage colony-stimulating factor-differentiated bone marrow-derived macrophage cultures were incubated 2 d with 50 µg/mL acetylated low-density lipoprotein (AcLDL)+5 μm TO901317 (TO9) to enrich macrophages with cholesterol. After rinsing, macrophage cultures were incubated 2 d with the indicated additions (100 µg/ mL peptide and 125 µg/mL sphingomyelin alone or complexed with 100 µg/mL peptide 5A [5A-SPH]) without AcLDL. Then, the macrophage total cholesterol content was determined, and the decrease in macrophage cholesterol content induced by the added peptide was calculated. Cholesterol contents before and after incubation with AcLDL, respectively, were 107±14 nmoles cholesterol/mg cell protein (10±2% cholesteryl ester) and 453±27 nmoles cholesterol/mg cell protein (70±0% cholesteryl ester) for ABCA1 +/+ macrophages and 146±26 nmoles cholesterol/mg cell protein (25±10% cholesteryl ester) and 571±7 nmoles cholesterol/mg cell protein (75±1% cholesteryl ester) for ABCA1 −/− macrophages. For ABCA1+/+ macrophages, 5A and 5A-SPH were significantly different than EE and SPH. For ABCA1 −/− macrophages, 5A-SPH was significantly different than 5A, SPH, and EE. EE indicates peptide EE; and f/b, followed by.
The choice of sphingomyelin as the phospholipid complexed to peptide 5A should be optimal for mobilization of cholesterol as this phospholipid has a relatively high affinity for cholesterol as compared with other common phospholipids. 51 However, sphingomyelin alone did not show any mobilization of extracellular cholesterol microdomain deposits or stimulate a decrease in macrophage cholesterol content. The sphingomyelin was added as liposomes. Such liposomes previously have been shown to be poor acceptors of cholesterol, most likely because of size constraints limiting access of these relatively large particles to sites of potential cholesterol efflux. 52, 53 In this regard, efficient delivery of cholesterol acceptors to sites of cholesterol accumulation within atherosclerotic plaques is also an obstacle to attaining plaque reverse cholesterol transport. Efficient delivery of cholesterol acceptors may not only be limited by acceptor size but also by loss of acceptor efflux potential as the acceptor passes through the blood and picks up cholesterol effluxed from other sites besides plaques such as liver 54 and the spleen that processes cholesterol from degraded red cells.
ApoA-I and ApoA-I mimetic peptides show a beneficial effect on the development of atherosclerosis in experimental animal models. 9, [55] [56] [57] [58] The mechanism of this effect may be multifactorial, including anti-inflammatory effects in addition to stimulating reverse cholesterol transport by mobilizing cellular and, as we have demonstrated here, extracellular cholesterol microdomains. If not mobilized, extracellular cholesterol microdomains could promote atherogenesis by promoting inflammation. The antibody used here to detect extracellular deposited cholesterol does not bind individual cholesterol molecules. Rather, this antibody labels a structural domain of organized cholesterol molecules as can occur for example in a cholesterol crystal. 59, 60 Although the physical form of the extracellular cholesterol microdomains deposited by macrophage has not yet been determined, high concentrations of cholesterol in crystals or liposomes can stimulate complement formation and thereby promote inflammation. [61] [62] [63] Thus, future studies of the potential inflammatory properties of the extracellular cholesterol microdomains is warranted.
In conclusion, previously we showed that both ABCA1 and ABCG1 mediate macrophage deposition of extracellular cholesterol microdomains. 4, 5 Our finding here that ABCA1 is necessary for mobilization of this cholesterol demonstrates an interesting concerted action of ABCA1, both to deposit and then effect mobilization of extracellular cholesterol microdomains. However, ApoA-I and ApoA-I mimetic peptides already complexed with phospholipid may show better efficacy for both cellular and extracellular plaque cholesterol removal when ABCA1 expression is limited.
